Ponatinib in Participants With Resistant Chronic Phase Chronic Myeloid Leukemia (CP-CML) to Characterize the Efficacy and Safety of a Range of Doses

The drug being tested in this study is ponatinib. This study will characterize the safety and
efficacy of ponatinib over a range of 3 starting doses.

The study will enroll 276 participants in 3 cohorts and each cohort will have 92
participants. All the participants will be randomized to receive once-daily oral
administration of 1 of 3 starting doses of ponatinib:

Cohort A: 45 mg ponatinib tablet Cohort B: 30 mg ponatinib tablet Cohort C: 15 mg ponatinib
tablet

The study is designed to consist of 2 periods: 24-cycle Main treatment period and optional
treatment continuation period. Participants will be treated with their randomized dose of
study drug in the Main Treatment Period until the occurrence of at least one of the
following: absence of complete hematologic response (CHR) by 3 months, absence of MCyR at 12
months, absence of <= 1% BCR-ABL1IS at 12 months, loss of <= 1% BCR-ABL1IS development of
intolerance, or completion of all 24 cycles of treatment (whichever occurs first). Following
completion of the 24-month main treatment period or following early withdrawal, participants
may enter into an optional treatment continuation period.

This multi-center trial will be conducted worldwide. The overall time to participate in this
study is approximately 60 months. Participants will make a final visit to the clinic
approximately 30 days after the last dose of study treatment.

Inclusion Criteria:

1. Have CP-CML and have received at least two prior tyrosine-kinase inhibitor (TKI)
therapies and have demonstrated resistance to treatment OR have documented history of
presence of T3151 mutation after receiving any number of prior TKI.

1. The diagnosis of CML will be made using standard hematopathologic and cytogenetic
criteria; CP-CML will be defined by all of the following:

i < 15% blasts in bone marrow. ii < 30% blasts plus promyelocytes in bone marrow.
iii < 20% basophils in peripheral blood. iv Greater than or equal to (>=) 100 ×
10^9/liter (L) platelets (>= 100,000/cubic millimeter [mm^3]).

v No evidence of extramedullary disease except hepatosplenomegaly. vi No prior
diagnosis of accelerated phase (AP-CML), and blastic phase (BP-CML)

2. Cytogenetic assessment at screening must demonstrate the BCR-ABL1 fusion by
presence of the t(9;22) Philadelphia chromosome.

i Variant translocations are only allowed provided they meet inclusion criterion
1d.

3. Resistance to prior TKI therapy is defined as follows (participants must meet at
least 1 criterion):

i Three months after the initiation of prior TKI therapy: No cytogenetic response
(> 95% Ph+) or failure to achieve CHR or new mutation.

ii Six months after the initiation of prior TKI therapy: BCR-ABL1IS >10% and/or
Ph+ >65% or new mutation.

iii Twelve months after the initiation of prior TKI therapy: BCR ABL1IS >10%
and/or Ph+ >35% or new mutation.

iv At any time after the initiation of prior TKI therapy, the development of a
new BCR-ABL1 kinase domain mutation(s).

v At any time after the initiation of prior TKI therapy, the development of new
clonal evolution vi At any time after the initiation of prior TKI therapy, the
loss of CHR, or CCyR, or the confirmed loss of MMR in 2 consecutive tests, one of
which has a BCR-ABL1IS transcript level of >=1% or new mutation.

4. > 1% of BCR-ABL1IS as shown by real-time polymerase chain reaction.

2. Have an Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1, or 2.

3. Have adequate renal function as defined by the following critera:

- Serum creatinine <=1.5 × upper limit of normal (ULN) for institution.

- Estimated creatinine clearance >= 30 milliliter per minute (mL/min)
(Cockcroft-Gault formula).

4. Have adequate hepatic function as defined by the following criteria:

- Total serum bilirubin <=1.5 × ULN, unless due to Gilbert's syndrome.

- Alanine transaminase (ALT) <= 2.5 × ULN, or <= 5 × ULN if leukemic infiltration
of the liver is present.

- Aspartate transaminase (AST) <= 2.5 × ULN, or <= 5 × ULN if leukemic infiltration
of the liver is present.

5. Have normal pancreatic status as defined by the following criterion:

a. Serum lipase and amylase <= 1.5 × ULN.

6. Have normal QT interval corrected (Frederica) (QTcF) interval on screening
electrocardiogram (ECG) evaluation, defined as QTcF of <= 450 milliseconds (ms) in
males or <= 470 ms in females.

7. Have recovered from toxicities related to prior anticancer therapy to National Cancer
Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) v 4.0 grade <=
1.

Exclusion Criteria:

1. Have used any approved TKIs or investigational agents within 2 weeks or 6 half-lives
of the agent, whichever is longer, prior to receiving study drug.

2. Received interferon, cytarabine, or immunotherapy within 14 days, or any other
cytotoxic chemotherapy, radiotherapy, or investigational therapy within 28 days prior
to receiving the first dose of ponatinib, or have not recovered (> grade 1 by NCI
CTCAE, version 4.0) from AEs (except alopecia), due to agents previously administered.

3. Have undergone autologous or allogeneic stem cell transplant <60 days prior to
receiving the first dose of ponatinib; have any evidence of ongoing graft-versus-host
disease (GVHD) or GVHD requiring immunosuppressive therapy or are being considered for
stem cell transplant within 6-12 months of enrollment (note: ponatinib is not to be
used as a bridge to stem cell transplant in this trial)

4. Are taking medications with a known risk of Torsades de Pointes.

5. Have clinically significant, uncontrolled, or active cardiovascular disease,
specifically including, but not restricted to:

- Any history of myocardial infarction (MI), unstable angina, cerebrovascular
accident, or Transient Ischemic Attack (TIA).

- Any history of peripheral vascular infarction, including visceral infarction.

- Any revascularization procedure, including the placement of a stent.

- Congestive heart failure (NYHA class III or IV) within 6 months prior to
enrollment, or left ventricular ejection fraction (LVEF) less than lower limit of
normal, per local institutional standards, within 6 months prior to enrollment.

- History of clinically significant (as determined by the treating physician)
atrial arrhythmia or any history of ventricular arrhythmia.

- Venous thromboembolism, including deep venous thrombosis or pulmonary embolism,
within 6 months prior to enrollment.

6. Have uncontrolled hypertension (that is, >150 and >90 for systolic blood pressure
(SBP) and diastolic blood pressure (DBP) respectively). Participants with hypertension
should be under treatment at study entry to ensure blood pressure control. Those
requiring 3 or more antihypertensive medications should be discussed with the medical
monitor.

7. Have poorly controlled diabetes defined as HbA1c values of > 7.5%. Participants with
preexisting, well-controlled diabetes are not excluded.

- Additional inclusion/exclusion criteria per protocol.